IP Library Granted Patent US 8,263,557
Granted Patent B2
US 8,263,557 · App. 12/227,079 · Granted Sep 11, 2012

Method and mixture for in vivo photochemical cross-linking of collagen

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,557
App. No.
12/227,079
Granted
Sep 11, 2012
Kind
B2
Abstract

A method and a composition for photochemical cross linking of collagen by photoactive agent in-vivo are presented. The method includes a non-toxic photoactive formulation of the composition with collagen, which is administered to treatment area locally; followed by irradiation with suitable wavelength. In one of the embodiment liposomal formulated mTHPC is added to the collagen and is irradiated with a 652 nm laser, resulting in producing efficient collagen scaffolds with strengthen and stabilized microstructure, thus improving the physiochemical properties of the collagen scaffold. It improves the thermostability, mechanical property and swelling ratio of newly formed scaffold. Photochemical cross-linked collagens shows antimicrobial effect, when irradiated with suitable wavelength it disinfects the treatment site and curbs microbial growth.

Claims (8)

1. A method for in vivo cross-linking of structural proteins comprising the steps of:

(a) formulating a mixture of a photosensitizer and said structural protein;

(b) applying said mixture to tissue to be treated in a patient;

(c) irradiating said treated tissue at a preselected wavelength;

(d) photoactivating said photosensitizer; and

(e) substantially simultaneously disinfecting the treatment site through photochemical reactions during photoactivation of said photosensitizer.

2. The method for in vivo cross-linking of structural proteins according to claim 1 , wherein said irradiating step is by exposure to electromagnetic radiation having a wavelength between about 530 nm and 750 nm, in which the preselected wavelength overlaps sufficiently with the wavelengths of said photosensitizer's absorption spectrum to activate said photosensitizer.

3. The method for in vivo cross-linking of structural proteins according to claim 1 , wherein said preselected wavelength is about 652 nm, said photosensitizer is temoporfin (mTHPC), and said structural protein is collagen.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2016
From: BIOLITEC PHARMA MARKETING LTD.
To: BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG
Reel/Frame 041182/0578 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2009
From: BIOLITEC, INC.
To: BIOLITEC PHARMA MARKETING LTD.
Reel/Frame 022482/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2009
From: CERAMOPTEC INDUSTRIES, INC.
To: BIOLITEC, INC.
Reel/Frame 022482/0956 →